Slingshot members are tracking this event:

European Commission Approves the First and Only Immuno-Oncology Combination, Bristol-Myers Squibb’s Opdivo (nivolumab) + Yervoy (ipilimumab) Regimen, for Treatment of Advanced Melanoma

Do you think this event is important to the companies below? How will it affect their stock price?

Related Companies
High Medium Low
Impact on Stocks
BMY Community voting in process

Additional Information

Additional Relevant Details The European Commission (EC) has approved Opdivo in combination with Yervoy for the treatment of advanced (unresectable or metastatic) melanoma in adults, representing the first and only approved combination of two Immuno-Oncology agents in the European Union (EU). This approval allows for the marketing of the Opdivo + Yervoy Regimen in all 28 Member States of the EU. Approval was based on CheckMate -067, the first Phase 3, double-blind, randomized study, in which the Opdivo + Yervoy Regimen and Opdivo monotherapy demonstrated superior progression-free survival (PFS) and objective response rates (ORR) in patients with advanced melanoma, regardless of BRAF mutational status, versus Yervoy alone. The safety profile was consistent with previously reported studies evaluating the Opdivo +Yervoy Regimen, and most treatment-related adverse events were managed using established algorithms.
Slingshot Insights Explained
Catalyst Date
Occurred on:
May 11, 2016
Related Projects Image
  • Don’t see a project related to the catalyst you care about?

Related Keywords Ipilimumab, Opdivo, Nivolumab